Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.

Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Gimenez-Cassina Lopez B, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium (TBCRC).

Clin Breast Cancer. 2019 Aug 22. pii: S1526-8209(19)30657-3. doi: 10.1016/j.clbc.2019.07.011. [Epub ahead of print]

PMID:
31558424
2.

Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.

Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, Chamness GC, Reis-Filho JS, Weigelt B, Heiser LM, Hilsenbeck SG, Huang S, Rimawi MF, Gray JW, Osborne CK, Schiff R.

Mol Cancer Res. 2019 Aug 16. doi: 10.1158/1541-7786.MCR-19-0756. [Epub ahead of print]

PMID:
31420371
3.

Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.

Niravath P, Hilsenbeck SG, Wang T, Jiralerspong S, Nangia J, Pavlick A, Ademuyiwa F, Frith A, Ma C, Park H, Rigden C, Suresh R, Ellis M, Kent Osborne C, Rimawi MF.

Breast Cancer Res Treat. 2019 Sep;177(2):427-435. doi: 10.1007/s10549-019-05319-4. Epub 2019 Jun 19.

PMID:
31218477
4.

HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.

Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF.

J Natl Cancer Inst. 2019 Apr 30. pii: djz042. doi: 10.1093/jnci/djz042. [Epub ahead of print]

PMID:
31037288
5.

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.

Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R.

Ann Oncol. 2019 Mar 23. pii: mdz076. doi: 10.1093/annonc/mdz076. [Epub ahead of print]

PMID:
30903140
6.

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium.

J Clin Oncol. 2019 May 1;37(13):1081-1089. doi: 10.1200/JCO.18.01511. Epub 2019 Mar 12.

PMID:
30860945
7.

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.

Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, Veeraraghavan J, Nagi C, Pilling M, Rimawi MF, Trivedi M, Hilsenbeck SG, Chamness GC, Jeselsohn R, Osborne CK, Schiff R.

Br J Cancer. 2019 Feb;120(3):331-339. doi: 10.1038/s41416-018-0354-9. Epub 2018 Dec 17.

PMID:
30555156
8.

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TF.

Nat Med. 2018 May;24(4):505-511. doi: 10.1038/nm.4507. Epub 2018 Mar 26.

9.

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.

Wapnir IL, Price KN, Anderson SJ, Robidoux A, Martín M, Nortier JWR, Paterson AHG, Rimawi MF, Láng I, Baena-Cañada JM, Thürlimann B, Mamounas EP, Geyer CE Jr, Gelber S, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S; International Breast Cancer Study Group; NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group; Breast International Group.

J Clin Oncol. 2018 Apr 10;36(11):1073-1079. doi: 10.1200/JCO.2017.76.5719. Epub 2018 Feb 14.

10.

Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.

Niravath P, Chen B, Chapman JW, Agarwal SK, Welschhans RL, Bongartz T, Kalari KR, Shepherd LE, Bartlett J, Pritchard K, Gelmon K, Hilsenbeck SG, Rimawi MF, Osborne CK, Goss PE, Ingle JN.

Clin Breast Cancer. 2018 Feb;18(1):78-87. doi: 10.1016/j.clbc.2017.10.009. Epub 2017 Oct 16.

PMID:
29128193
11.

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R.

Breast Cancer Res Treat. 2018 Feb;167(3):731-740. doi: 10.1007/s10549-017-4533-9. Epub 2017 Nov 7.

12.

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.

Veeraraghavan J, De Angelis C, Reis-Filho JS, Pascual T, Prat A, Rimawi MF, Osborne CK, Schiff R.

Breast. 2017 Aug;34 Suppl 1:S19-S26. doi: 10.1016/j.breast.2017.06.022. Epub 2017 Jul 4. Review.

13.

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.

Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R.

Clin Cancer Res. 2017 Sep 1;23(17):5123-5134. doi: 10.1158/1078-0432.CCR-16-2191. Epub 2017 May 9.

14.

Retrospective review of genomic testing in breast cancer: Does it improve outcome?

Gastelum GM, Iqbal C, Hilsenbeck SG, Rimawi MF, Niravath P.

Breast Cancer Res Treat. 2017 May;163(1):191-195. doi: 10.1007/s10549-017-4154-3. Epub 2017 Feb 21.

PMID:
28224382
15.

Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions.

Soleja M, Rimawi MF.

Curr Probl Cancer. 2016 Mar - Aug;40(2-4):117-129. doi: 10.1016/j.currproblcancer.2016.09.005. Epub 2016 Sep 19. Review.

PMID:
27839746
16.

Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes.

Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K.

Cancer Res. 2016 Nov 15;76(22):6495-6506. doi: 10.1158/0008-5472.CAN-16-1457. Epub 2016 Sep 26.

17.

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.

Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, Tsimelzon A, Gutierrez C, Huang S, Edwards DP, Trivedi MV, Rimawi MF, Lopez-Terrada D, Hilsenbeck SG, Gray JW, Brown M, Osborne CK, Schiff R.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6600-E6609. Epub 2016 Oct 6.

18.

TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.

Mitri Z, Nanda R, Blackwell K, Costelloe CM, Hood I, Wei C, Brewster AM, Ibrahim NK, Koenig KB, Hortobagyi GN, Van Poznak C, Rimawi MF, Moulder-Thompson S; Translational Breast Cancer Research Consortium.

Clin Cancer Res. 2016 Dec 1;22(23):5706-5712. Epub 2016 May 10.

19.

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU.

J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1.

20.

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).

Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD.

J Clin Oncol. 2015 Aug 20;33(24):2623-31. doi: 10.1200/JCO.2014.60.0353. Epub 2015 Jul 13.

21.

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.

Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, Lopez-Tarruella S, Pavlick AC, Trivedi MV, Chamness GC, Chang JC, Osborne CK, Rimawi MF, Schiff R.

Clin Cancer Res. 2015 Sep 1;21(17):3995-4003. doi: 10.1158/1078-0432.CCR-14-2728. Epub 2015 May 26.

22.

Resistance to Anti-HER2 Therapies in Breast Cancer.

Rimawi MF, De Angelis C, Schiff R.

Am Soc Clin Oncol Educ Book. 2015:e157-64. doi: 10.14694/EdBook_AM.2015.35.e157. Review.

23.

Targeting HER2 for the treatment of breast cancer.

Rimawi MF, Schiff R, Osborne CK.

Annu Rev Med. 2015;66:111-28. doi: 10.1146/annurev-med-042513-015127. Review.

PMID:
25587647
24.

Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.

Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, Mitchell T, Bhat R, Zhang X, Mao S, Dobrolecki LE, Al-rawi A, Chen F, Veneziani BM, Zhang XH, Hilsenbeck SG, Contreras A, Gutierrez C, Jeselsohn RM, Rimawi MF, Osborne CK, Lewis MT, Schiff R, Trivedi MV.

Breast Cancer Res. 2015 Jan 9;17:3. doi: 10.1186/s13058-014-0508-5.

25.

A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.

Rimawi MF, Aleixo SB, Rozas AA, Nunes de Matos Neto J, Caleffi M, Figueira AC, Souza SC, Reiriz AB, Gutierrez C, Arantes H, Uttenreuther-Fischer MM, Solca F, Osborne CK.

Clin Breast Cancer. 2015 Apr;15(2):101-9. doi: 10.1016/j.clbc.2014.11.004. Epub 2014 Nov 15.

PMID:
25537159
26.

Circulating tumor cell analysis in metastatic triple-negative breast cancers.

Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS; Translational Breast Cancer Research Consortium.

Clin Cancer Res. 2015 Mar 1;21(5):1098-105. doi: 10.1158/1078-0432.CCR-14-1948. Epub 2014 Dec 18. Erratum in: Clin Cancer Res. 2015 Jul 15;21(14):3356-7.

27.

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.

Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.

Breast Cancer Res. 2014 Sep 11;16(5):430. doi: 10.1186/s13058-014-0430-x.

28.

Aromatase inhibitor adverse effects: are we sweeping them under the rug?

Niravath P, Rimawi MF, Osborne CK.

J Clin Oncol. 2014 Nov 20;32(33):3779. doi: 10.1200/JCO.2014.56.9640. Epub 2014 Aug 25. No abstract available.

PMID:
25154832
29.

Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.

Morrison G, Fu X, Shea M, Nanda S, Giuliano M, Wang T, Klinowska T, Osborne CK, Rimawi MF, Schiff R.

Breast Cancer Res Treat. 2014 Apr;144(2):263-72. doi: 10.1007/s10549-014-2878-x. Epub 2014 Feb 20.

30.

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

Aebi S, Gelber S, Anderson SJ, Láng I, Robidoux A, Martín M, Nortier JW, Paterson AH, Rimawi MF, Cañada JM, Thürlimann B, Murray E, Mamounas EP, Geyer CE Jr, Price KN, Coates AS, Gelber RD, Rastogi P, Wolmark N, Wapnir IL; CALOR investigators.

Lancet Oncol. 2014 Feb;15(2):156-63. doi: 10.1016/S1470-2045(13)70589-8. Epub 2014 Jan 16.

31.

A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.

Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT.

Cancer Res. 2013 Aug 1;73(15):4885-97. doi: 10.1158/0008-5472.CAN-12-4081. Epub 2013 Jun 4.

32.

Predictors of post-mastectomy reconstruction in an underserved population.

Wolfswinkel EM, Lopez SN, Weathers WM, Qashqai S, Wang T, Hilsenbeck SG, Rimawi MF, Heller L.

J Plast Reconstr Aesthet Surg. 2013 Jun;66(6):763-9. doi: 10.1016/j.bjps.2013.02.018. Epub 2013 Apr 10.

PMID:
23582504
33.

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.

Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC.

J Clin Oncol. 2013 May 10;31(14):1726-31. doi: 10.1200/JCO.2012.44.8027. Epub 2013 Apr 8.

34.

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.

Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, Osborne CK, De Placido S, Arpino G.

Breast Cancer Res Treat. 2012 Dec;136(3):795-804. doi: 10.1007/s10549-012-2315-y. Epub 2012 Nov 4.

35.

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP.

J Clin Oncol. 2012 Jul 20;30(21):2615-23. doi: 10.1200/JCO.2010.34.5579. Epub 2012 Jun 4.

36.

Jejunal intussusception due to malignant phyllodes tumor of the breast.

Bilen MA, Laucirica R, Rimawi MF, Nangia JR, Cyprus GS.

Clin Breast Cancer. 2012 Jun;12(3):219-21. doi: 10.1016/j.clbc.2012.01.007. Epub 2012 Feb 28.

PMID:
22381472
37.

Breast Cancer: Blocking both driver and escape pathways improves outcomes.

Rimawi MF, Osborne CK.

Nat Rev Clin Oncol. 2012 Feb 14;9(3):133-4. doi: 10.1038/nrclinonc.2012.9. No abstract available.

PMID:
22330685
38.

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.

Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28.

39.

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.

Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R.

Breast Cancer Res. 2011 Aug 31;13(4):R84. doi: 10.1186/bcr2936.

40.

High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.

Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, Carboni JM, Gottardis MM, Huang F, Chang JC, Lewis MT, Rimawi MF, Lee AV.

Clin Cancer Res. 2011 Apr 15;17(8):2314-27. doi: 10.1158/1078-0432.CCR-10-1903. Epub 2010 Dec 22.

41.

Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.

Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R.

Clin Cancer Res. 2011 Mar 15;17(6):1351-61. doi: 10.1158/1078-0432.CCR-10-1905. Epub 2010 Dec 7.

42.

Self-blame, self-forgiveness, and spirituality in breast cancer survivors in a public sector setting.

Friedman LC, Barber CR, Chang J, Tham YL, Kalidas M, Rimawi MF, Dulay MF, Elledge R.

J Cancer Educ. 2010 Sep;25(3):343-8. doi: 10.1007/s13187-010-0048-3. Epub 2010 Feb 26.

PMID:
20186521
43.

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.

Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, Elledge RM.

Cancer. 2010 Mar 1;116(5):1234-42. doi: 10.1002/cncr.24816.

Supplemental Content

Loading ...
Support Center